BR0308904A - Método de tratamento de gastroparesia, e, uso de um composto de glp-1 - Google Patents

Método de tratamento de gastroparesia, e, uso de um composto de glp-1

Info

Publication number
BR0308904A
BR0308904A BR0308904-5A BR0308904A BR0308904A BR 0308904 A BR0308904 A BR 0308904A BR 0308904 A BR0308904 A BR 0308904A BR 0308904 A BR0308904 A BR 0308904A
Authority
BR
Brazil
Prior art keywords
glp
gastroparesis
treatment
compound
compounds
Prior art date
Application number
BR0308904-5A
Other languages
English (en)
Inventor
Joseph Anthony Jakubowski
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0308904A publication Critical patent/BR0308904A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO DE TRATAMENTO DE GASTROPARESIA, E, USO DE UM COMPOSTO DE GLP- 1". A invenção refere-se ao uso de compostos de GLP-1 para o tratamento de gastroparesia. Paciente com gastroparesia em geral experimenta um retardamento no esvaziamento gástrico. Compostos de GLP-1 podem ser utilizados para o esvaziamento gástrico nestes pacientes.
BR0308904-5A 2002-04-10 2003-03-27 Método de tratamento de gastroparesia, e, uso de um composto de glp-1 BR0308904A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (1)

Publication Number Publication Date
BR0308904A true BR0308904A (pt) 2005-05-03

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308904-5A BR0308904A (pt) 2002-04-10 2003-03-27 Método de tratamento de gastroparesia, e, uso de um composto de glp-1

Country Status (18)

Country Link
US (1) US20050164925A1 (pt)
EP (1) EP1496924A4 (pt)
JP (1) JP2005530732A (pt)
KR (1) KR20040098063A (pt)
CN (1) CN1735423A (pt)
AU (1) AU2003220403A1 (pt)
BR (1) BR0308904A (pt)
CA (1) CA2480858A1 (pt)
EA (1) EA200401345A1 (pt)
EC (1) ECSP045345A (pt)
HR (1) HRP20040939A2 (pt)
IL (1) IL164266A0 (pt)
MX (1) MXPA04009929A (pt)
NO (1) NO20044815L (pt)
NZ (1) NZ535684A (pt)
PL (1) PL373658A1 (pt)
WO (1) WO2003087139A2 (pt)
ZA (1) ZA200408111B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
EP1793891B1 (en) 2004-08-18 2011-11-09 Metacure Limited Monitoring, analysis, and regulation of eating habits
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
US9339190B2 (en) 2005-02-17 2016-05-17 Metacure Limited Charger with data transfer capabilities
CN101128214A (zh) 2005-03-18 2008-02-20 诺和诺德公司 长效glp-1化合物
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2006102626A2 (en) * 2005-03-24 2006-09-28 Metacure Nv Wireless leads for gastrointestinal tract applications
WO2007080595A2 (en) 2006-01-12 2007-07-19 Metacure N.V. Electrode assemblies, tools, and methods for gastric wall implantation
US8301256B2 (en) 2005-06-02 2012-10-30 Metacure Limited GI lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
US8288339B2 (en) * 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
WO2008139463A2 (en) * 2007-05-09 2008-11-20 Metacure Ltd. Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
BRPI0917000A2 (pt) 2008-08-06 2016-02-16 Novo Nordisk Healthcare Ag proteínas conjugadas com eficácia in vivo prolongada
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
US8642548B2 (en) * 2009-08-07 2014-02-04 Mannkind Corporation Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
CA2787895A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
CN102869676A (zh) 2010-04-30 2013-01-09 株式会社三和化学研究所 用于提高生理活性物质等的生物体内稳定性的肽和提高了生物体内稳定性的生理活性物质
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
NZ535684A (en) 2006-03-31
IL164266A0 (en) 2005-12-18
EP1496924A4 (en) 2007-05-30
US20050164925A1 (en) 2005-07-28
EP1496924A2 (en) 2005-01-19
KR20040098063A (ko) 2004-11-18
EA200401345A1 (ru) 2005-08-25
PL373658A1 (en) 2005-09-05
ZA200408111B (en) 2005-10-07
JP2005530732A (ja) 2005-10-13
NO20044815L (no) 2005-01-07
MXPA04009929A (es) 2006-03-10
CA2480858A1 (en) 2003-10-23
ECSP045345A (es) 2006-04-19
AU2003220403A1 (en) 2003-10-27
WO2003087139A3 (en) 2004-01-08
HRP20040939A2 (en) 2004-12-31
WO2003087139A2 (en) 2003-10-23
CN1735423A (zh) 2006-02-15

Similar Documents

Publication Publication Date Title
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
MXPA03003870A (es) Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
DE60026704D1 (de) (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
IL158593A0 (en) Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
GB0225474D0 (en) Therapeutic agents
WO2002096363A3 (en) Method for treating fibrotic diseases or other indications
WO2003049702A3 (en) Vanilloid receptor ligands and their use in treatments
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
AU2000276362A1 (en) Composition for the treatment of diabetes
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
GB9907571D0 (en) Compounds
SE0004101D0 (sv) New use
AU4937699A (en) Use of succinic acid or salts thereof for the treatment of diabetes mellitus andwound healing
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A,4A, 5A,6A E 7A ANUIDADES

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2051 DE 27/04/2010. TEXTO CORRETO: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.10 DA RPI 2068 DE 24/08/2010.